{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-010226","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2024-01-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.924743+00:00","generated_at":"2026-06-06T21:57:25.701819+00:00","sec_items":["3.01"],"event_type":"other","sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Spyre Therapeutics transfers listing to Nasdaq Global Select Market effective Jan 19, 2024","bullets":["Received approval from Nasdaq to transfer listing from Capital Market to Global Select Market.","Effective at the opening of business on January 19, 2024.","Common stock continues to trade under the symbol SYRE.","Transfer indicates the company met stricter financial requirements for higher-tier market."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-010226","json":"https://secwatch.observer/filing/0001193125-24-010226.json","markdown":"https://secwatch.observer/filing/0001193125-24-010226.md","text":"https://secwatch.observer/filing/0001193125-24-010226.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000119312524010226/0001193125-24-010226-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000119312524010226/d700531d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T21:57:25.701819+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}